8-HOUR BAYER

LOE Approaching

aspirin

NDAORALTABLET, EXTENDED RELEASE
Approved
Jun 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Clinical Trials (5)

NCT07089862N/ANot Yet Recruiting

INdobufen Versus asPirin in Endovascular Unruptured Intracranial Aneurysms Treatment (INPUT)

Started Aug 2025
NCT06444178Phase 1Completed

Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants

Started Sep 2024
224 enrolled
Healthy Volunteers
NCT05546957N/ACompleted

Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban in Healthy Adult Participants

Started Jan 2023
60 enrolled
Healthy Volunteer
NCT05093790Phase 2Completed

A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy Participants

Started Mar 2022
58 enrolled
Coronary Artery DiseaseHealthy Participants
NCT05080946Phase 1Recruiting

Using Aspirin to Improve Immunological Features of Ovarian Tumors

Started Nov 2021
100 enrolled
Ovarian CancerFallopian Tube CancerPeritoneal Cancer